Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
Tempest Therapeutics, Inc. (TPST) to present at the 44th Annual TD Cowen Healthcare Conference on March 4, 2024, focusing on cancer therapeutics development.
02/26/2024 - 08:00 AM
BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that Stephen Brady, president and chief executive officer of Tempest, will present at the 44th Annual TD Cowen Healthcare Conference on Monday, March 4, 2024 at 9:10 a.m. ET.
To access the live or archived recording of the presentation, please visit the investor section of the Tempest website at https://ir.tempesttx.com
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com
Investor & Media Contacts
Sylvia Wheeler
Aljanae Reynolds
When will Tempest Therapeutics present at the 44th Annual TD Cowen Healthcare Conference?
Tempest Therapeutics will present on March 4, 2024, at 9:10 a.m. ET.
What is Tempest Therapeutics' ticker symbol?
Tempest Therapeutics' ticker symbol is TPST.
Where can investors access the presentation recording?
Investors can access the live or archived recording on the Tempest website at https://ir.tempesttx.com.
What is Tempest Therapeutics focused on developing?
Tempest Therapeutics is developing first-in-class targeted and immune-mediated therapeutics to fight cancer.
TPST Rankings
#91 Ranked by Stock Gains
TPST Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
United States
City
Ann Arbor
About TPST
tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.
